Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
A Phase IIa, Multi-center, Multi-national, Open Label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty
Sponsor: Daiichi Sankyo
Listed as NCT00107900, this PHASE2 trial focuses on Arthroplasty, Replacement, Hip and Thrombosis and remains completed. Sponsored by Daiichi Sankyo, it has been updated 10 times since 2005, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2024 [monthly]
Completed PHASE2
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Feb 2019 — Mar 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jan 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .